BioCryst Pharmaceuticals Inc (BCRX) stock
BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.50+0.05 (+0.67%)
Close on Nov 17, 2026Market cap $1.92BP/E –Yield –
BioCryst Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
BioCryst Pharmaceuticals's cash was $352.57M at Jun 30, 2026. For fiscal 2025 it was $274.75M, down 14.8% from the year before. Over ten years it grew 18.2% a year on average. The highest annual figure on record is $507.60M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $274.75M | -14.8% |
| FY2024 | Dec 31, 2024 | $322.46M | -17.1% |
| FY2023 | Dec 31, 2023 | $388.99M | -8.6% |
| FY2022 | Dec 31, 2022 | $425.78M | -16.1% |
| FY2021 | Dec 31, 2021 | $507.60M | +69.0% |
| FY2020 | Dec 31, 2020 | $300.37M | +120.5% |
| FY2019 | Dec 31, 2019 | $136.23M | +30.4% |
| FY2018 | Dec 31, 2018 | $104.47M | -8.7% |
| FY2017 | Dec 31, 2017 | $114.40M | +109.3% |
| FY2016 | Dec 31, 2016 | $54.65M | +6.0% |
| FY2015 | Dec 31, 2015 | $51.56M | -29.1% |
| FY2014 | Dec 31, 2014 | $72.77M | +91.2% |
| FY2013 | Dec 31, 2013 | $38.06M | +6.9% |
| FY2012 | Dec 31, 2012 | $35.60M | -14.7% |
| FY2011 | Dec 31, 2011 | $41.72M | -22.7% |
| FY2010 | Dec 31, 2010 | $53.95M | +31.2% |
| FY2009 | Dec 31, 2009 | $41.13M | +84.1% |
| FY2008 | Dec 31, 2008 | $22.34M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $352.57M | +35.6% |
| Q1 FY2026 | Mar 31, 2026 | $238.40M | -19.2% |
| Q4 FY2025 | Dec 31, 2025 | $274.75M | -14.8% |
| Q3 FY2025 | Sep 30, 2025 | $212.87M | -35.5% |
| Q2 FY2025 | Jun 30, 2025 | $260.04M | -4.4% |
| Q1 FY2025 | Mar 31, 2025 | $295.09M | -12.3% |
| Q4 FY2024 | Dec 31, 2024 | $322.46M | -17.1% |
| Q3 FY2024 | Sep 30, 2024 | $330.01M | -17.0% |
| Q2 FY2024 | Jun 30, 2024 | $272.03M | -33.8% |
| Q1 FY2024 | Mar 31, 2024 | $336.55M | -15.5% |
| Q4 FY2023 | Dec 31, 2023 | $388.99M | -8.6% |
| Q3 FY2023 | Sep 30, 2023 | $397.59M | -6.9% |
| Q2 FY2023 | Jun 30, 2023 | $410.67M | -1.6% |
| Q1 FY2023 | Mar 31, 2023 | $398.16M | -10.2% |
| Q4 FY2022 | Dec 31, 2022 | $425.78M | -16.1% |
| Q3 FY2022 | Sep 30, 2022 | $426.86M | +113.9% |
| Q2 FY2022 | Jun 30, 2022 | $417.48M | +91.1% |
| Q1 FY2022 | Mar 31, 2022 | $443.47M | +84.5% |
| Q4 FY2021 | Dec 31, 2021 | $507.60M | +69.0% |
| Q3 FY2021 | Sep 30, 2021 | $199.60M | +39.3% |
| Q2 FY2021 | Jun 30, 2021 | $218.43M | +15.3% |
| Q1 FY2021 | Mar 31, 2021 | $240.36M | +112.6% |
| Q4 FY2020 | Dec 31, 2020 | $300.37M | +120.5% |
| Q3 FY2020 | Sep 30, 2020 | $143.32M | +109.4% |
| Q2 FY2020 | Jun 30, 2020 | $189.40M | +105.5% |
| Q1 FY2020 | Mar 31, 2020 | $113.06M | +5.1% |
| Q4 FY2019 | Dec 31, 2019 | $136.23M | +30.4% |
| Q3 FY2019 | Sep 30, 2019 | $68.44M | -43.1% |
| Q2 FY2019 | Jun 30, 2019 | $92.15M | +14.1% |
| Q1 FY2019 | Mar 31, 2019 | $107.56M | +17.8% |
| Q4 FY2018 | Dec 31, 2018 | $104.47M | -8.7% |
| Q3 FY2018 | Sep 30, 2018 | $120.32M | -25.6% |
| Q2 FY2018 | Jun 30, 2018 | $80.74M | +0.1% |
| Q1 FY2018 | Mar 31, 2018 | $91.31M | -7.5% |
| Q4 FY2017 | Dec 31, 2017 | $114.40M | +109.3% |
| Q3 FY2017 | Sep 30, 2017 | $161.62M | +206.0% |
| Q2 FY2017 | Jun 30, 2017 | $80.67M | – |
| Q1 FY2017 | Mar 31, 2017 | $98.68M | – |
| Q4 FY2016 | Dec 31, 2016 | $54.65M | – |
| Q3 FY2016 | Sep 30, 2016 | $52.82M | – |
See a number that looks wrong?